Almost all of the C15 research covered on this site so far concerns the heart, the liver, metabolism, or cellular aging. The kidney has been essentially absent from the literature. A 2026 paper in Experimental and Therapeutic Medicine is the first study to test whether a C15-rich oil does anything for kidney function, using a standard rodent model of chronic kidney disease [1].
The short version: two blood markers of kidney function improved, the animals held their weight better, and nothing else reached statistical significance. That is a modest, early result, and the details matter more than the headline.
What Was Actually Tested
The test substance was not a generic C15 supplement. It was Pentadecyl, a trademarked triglyceride oil derived from Aurantiochytrium limacinum, a marine microorganism. The oil is composed primarily of odd-numbered fatty acids, with pentadecanoic acid as the main one. That distinction matters when reading the result: the animals received a whole oil containing a mix of odd-chain fatty acids in triglyceride form, not isolated C15 in the form most human supplements use.
The same ingredient had previously been reported to improve glucose tolerance in a mouse model of type 2 diabetes and to promote collagen production in human skin cells. Kidney disease had not been looked at before this paper.
The model was the 5/6 nephrectomized mouse, in which roughly five-sixths of functional kidney mass is surgically removed. The remaining tissue is forced to compensate, and the animals reliably develop the hallmarks of progressive chronic kidney disease. It is a well-established and fairly aggressive model. The mice received the oil at 0.2 grams per liter, suspended in their drinking water, for eight weeks.
What Improved
Two standard blood markers of kidney function were measured: blood urea nitrogen and serum creatinine. Both rise when the kidneys are failing to clear waste products, and both were significantly elevated in the untreated surgical animals, confirming the model worked as intended. In the treated animals, the rise in both markers was blunted.
The treated mice also gained body weight significantly better than untreated controls. That is a more meaningful finding than it sounds. Progressive kidney disease drives wasting, and the researchers reported that food and water intake were similar between groups, which means the weight difference was not simply the treated animals eating more.
What Did Not Improve
Survival did not differ between groups. The researchers ran a log-rank test and found no significant difference, meaning the treatment did not measurably extend life in this model over eight weeks.
The tissue-level findings were also weaker than the blood markers. Under the microscope, the surgical animals showed the expected structural damage: enlarged glomeruli (the filtering units) and dilated tubules. When the researchers compared average glomerular and tubular areas between treated and untreated animals, there was no significant difference. What they reported instead was a descriptive observation from the distribution analysis: the treated group appeared to have fewer of the most enlarged tubular profiles.
That word “descriptively” is doing real work. A shift in a distribution that does not move the group average, and that is reported without a supporting statistical test, is a hypothesis for the next study rather than a finding. It is worth noting that the researchers reported it honestly as such rather than dressing it up.
Is There a Plausible Mechanism?
Nothing in this study identifies how the effect happened, so any mechanism is inference from the broader C15 literature. The general picture from independent reviews is that C15 supplementation has been associated with improved insulin sensitivity, AMPK pathway activation, and reduced pro-inflammatory cytokine levels across several disease models [2].
Chronic kidney disease has a substantial inflammatory and metabolic component, so a compound with anti-inflammatory and metabolic activity producing a modest signal on kidney function markers is biologically coherent. Coherent is not the same as demonstrated. This study did not measure inflammatory markers in kidney tissue, so the connection remains an assumption.
Reading This Honestly
This is a single mouse study, in a surgical model, with a specific commercial oil, measuring surrogate blood markers over eight weeks. Blood urea nitrogen and creatinine are legitimate and standard kidney function markers, but they are markers. They are not the same as slowing progression to dialysis, and this study explicitly found no survival benefit.
Pentadecyl is a branded commercial ingredient, and the paper’s conflict statement discloses research support from Sea Act Co., Ltd. to the senior author, with company staff among the authors. Anyone evaluating this result should weigh that industry link.
Most importantly for anyone actually living with kidney disease: this result does not support taking C15 for kidney problems. Chronic kidney disease changes how the body handles many supplements, protein, minerals, and fluids, and supplement decisions in that context belong with a nephrologist who knows your labs. Nothing here has been tested in a human kidney patient. What this study genuinely earns is a place on the list of things worth testing next, which is exactly where it currently sits.
Who Paid for the Study
The PubMed record for the 2026 Experimental and Therapeutic Medicine paper (Yoneda-Yasui and colleagues) does carry a conflict-of-interest statement: the senior author, Yasuhiro Kosuge, received research support from Sea Act Co., Ltd. in Japan, and the author list includes three Sea Act employees from its research and development division, along with a team at the School of Pharmacy of Nihon University. Pentadecyl is described in the paper as derived from Aurantiochytrium limacinum, and Sea Act appears in the author affiliations of other Pentadecyl research as well. That does not make the findings wrong. Industry-supported animal studies are common, and the authors disclosed it. It does mean the result is a company-supported early finding about a commercial oil that has not yet been repeated by an independent group, and readers should weigh it accordingly.
Other Pentadecyl Work: Cells, Not Kidneys
A second Pentadecyl paper, published in 2025 in International Immunopharmacology (Tsuruta and colleagues), looked at BV-2 mouse microglial cells, the brain’s resident immune cells, exposed to a bacterial toxin that triggers inflammation. Pentadecyl did not reduce cell viability, and it selectively lowered the toxin-induced rise in interleukin-6 and interleukin-1 beta, while tumor necrosis factor alpha was unchanged. It also reduced activation of a signaling protein called STAT3 but did not affect p65, p38 or JNK, which are other inflammatory pathways. The authors compared the effect with a known STAT3 inhibitor and concluded Pentadecyl works at least partly through that pathway in these cells. This is a cell culture experiment, so it says nothing directly about kidney function, but it adds a plausible, testable lead: if a STAT3-related anti-inflammatory action exists, the next kidney experiment could measure it in kidney tissue, which the mouse study did not do.
What We Know About Odd-Chain Fatty Acids and Kidney Function in People
Human data on this exact question are sparse, and the few papers that exist are cautious. A 2021 analysis in Nutrition, Metabolism and Cardiovascular Diseases (van Westing and colleagues) followed 2,329 Dutch patients aged 60 to 80 after a heart attack in the Alpha Omega Cohort and tracked estimated kidney filtration rate over roughly 40 months, comparing it with the fatty acid mix in their blood. The combined odd-chain fatty acids, pentadecanoic and heptadecanoic acid, made up only about 0.2 percent of total fatty acids in that analysis, and their association with kidney function decline was weaker and not statistically significant. The one fatty acid with a statistically significant link was linoleic acid, an omega-6 fat, with a smaller decline in filtration rate in patients with higher levels. That is an observational association in a specific group of heart patients, not a test of supplementation.
A small 2024 study in Nutrients (Sledzinski and colleagues) followed 25 patients with chronic kidney disease through kidney transplantation and measured serum fatty acids before surgery and again at 3 months and 6 to 12 months afterward. Odd-chain fatty acids rose over the longer follow-up, while ultra-long-chain fatty acids fell. The authors suggest more detailed work could eventually guide diet or supplementation, but the study did not test C15 as a treatment and cannot show whether the change helped the patients. Taken together, the human literature shows only that kidney disease and kidney replacement are accompanied by shifts in blood fatty acid patterns, and that nobody has yet run a trial of C15 for kidney outcomes.
Why Mouse Kidney Markers Need Careful Interpretation
There are some reasons to read the improvement in blood urea nitrogen and creatinine with caution, in addition to the points already made. Creatinine is produced by muscle and cleared by the kidney, so differences in body weight and muscle mass between groups can influence it. The treated mice gained more weight than untreated controls, which the authors report as a benefit, but a change in lean mass could also nudge creatinine independent of true filtration. This is general physiology and not something the paper claims, and it illustrates why researchers usually add direct measures of filtration, urine protein and tissue damage scores. The study reported that the average glomerular and tubular areas did not differ between treated and untreated animals, so the structural evidence did not confirm a protective effect on average.
The dose is also hard to translate. The oil was supplied at 0.2 grams per liter in drinking water for eight weeks, and the abstract does not state how much each mouse actually consumed or what that corresponds to in a person. Because the oil is a triglyceride mixture of several odd-chain fatty acids, the contribution of pentadecanoic acid alone is unknown.
What Safety Data Exist for C15 Itself
For readers wondering whether C15 is safe in general, a 2024 randomized trial in the Journal of Nutrition (Robinson et al.) gave 200 mg of C15 daily for 12 weeks to 30 young adults with overweight or obesity and reported no significant adverse events, along with higher circulating C15. A 2021 rat toxicology study in Food and Chemical Toxicology (Matulka et al.) fed an odd-chain algal oil, made mostly of pentadecanoic and heptadecanoic acids, for 13 weeks at up to 15 percent of the diet and found no adverse effects and no genotoxicity. Neither abstract describes kidney outcomes in detail, and neither studied people with kidney disease. A healthy young adult cohort and healthy rats are not good proxies for someone with reduced filtration, whose handling of minerals, protein and many supplements may differ.
A Practical Bottom Line
- The mouse result is hypothesis-generating: two blood markers moved, survival did not.
- No human kidney trial of C15 or Pentadecyl has been located, and the human observational data do not show a clear kidney link for odd-chain fatty acids.
- If you have chronic kidney disease, take supplement questions to your nephrologist, who can interpret them against your labs and medications.
- Watch for the next steps: a replication by an independent lab, measures of inflammation in kidney tissue, and a dose comparison with pure C15.
Does C15 help kidney disease?
That has not been shown. One 2026 mouse study found that an odd-chain oil lowered blood urea nitrogen and creatinine in a surgical kidney disease model, but survival did not differ and no human kidney trial of C15 has been found.
Was the Pentadecyl kidney study independently funded?
Its conflict statement says the senior author received research support from Sea Act Co., Ltd., and Sea Act employees are listed among the authors. That is disclosed, and independent replication would strengthen the result.
Is the Pentadecyl oil the same as a C15 supplement?
No. Pentadecyl is a branded triglyceride oil from a marine microorganism that is mostly odd-chain fatty acids with pentadecanoic acid as the main one, while capsule supplements usually deliver isolated pentadecanoic acid.
References
- Renal function-improving action of Pentadecyl, a multifunctional triglyceride from Aurantiochytrium limacinum, in a mouse model of chronic kidney disease. Experimental and Therapeutic Medicine, 2026
- New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review. Biochimie, 2024
- Tsuruta K et al. Pentadecyl®, an odd-chain-rich triglyceride mixture derived from Aurantiochytrium oil, attenuates lipopolysaccharide-induced inflammatory cytokine production in BV-2 microglial cells. International immunopharmacology (2025). PMID 40349404
- van Westing AC et al. Plasma fatty acids and kidney function decline in post-myocardial infarction patients of the Alpha Omega Cohort. Nutrition, metabolism, and cardiovascular diseases : NMCD (2021). PMID 33744039
- Śledziński M et al. The Long-Term Effect of Kidney Transplantation on the Serum Fatty Acid Profile. Nutrients (2024). PMID 39408286
- Robinson MK et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of nutrition (2024). PMID 39069269
- Matulka RA et al. Safety evaluation of odd-chain fatty acid algal oil. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2021). PMID 34332011
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
